Sorrento Therapeutics, Inc.
SRNE
$0.0009
-$0.0001-10.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 64.27M | 60.71M | 62.84M | 60.32M | 54.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.27M | 60.71M | 62.84M | 60.32M | 54.98M |
| Cost of Revenue | 221.74M | 234.19M | 254.93M | 262.44M | 239.01M |
| Gross Profit | -157.47M | -173.48M | -192.09M | -202.11M | -184.03M |
| SG&A Expenses | 193.54M | 192.74M | 182.09M | 197.30M | 195.63M |
| Depreciation & Amortization | 4.51M | 4.42M | 4.33M | 4.23M | 4.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 419.79M | 431.34M | 441.34M | 463.97M | 438.75M |
| Operating Income | -355.52M | -370.64M | -378.50M | -403.65M | -383.77M |
| Income Before Tax | -571.59M | -684.25M | -580.17M | -529.16M | -557.13M |
| Income Tax Expenses | 9.31M | 7.59M | -2.42M | -33.66M | -32.26M |
| Earnings from Continuing Operations | -580.90 | -691.84 | -577.76 | -495.50 | -524.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 32.81M | 20.20M | 4.91M | 1.94M | 1.08M |
| Net Income | -548.10M | -671.64M | -572.84M | -493.57M | -523.79M |
| EBIT | -355.52M | -370.64M | -378.50M | -403.65M | -383.77M |
| EBITDA | -341.60M | -357.07M | -365.26M | -390.90M | -370.83M |
| EPS Basic | -1.09 | -1.46 | -1.32 | -1.33 | -1.53 |
| Normalized Basic EPS | -0.42 | -0.50 | -0.59 | -0.69 | -0.74 |
| EPS Diluted | -1.10 | -1.47 | -1.33 | -1.33 | -1.53 |
| Normalized Diluted EPS | -0.42 | -0.50 | -0.59 | -0.69 | -0.74 |
| Average Basic Shares Outstanding | 2.03B | 1.88B | 1.68B | 1.50B | 1.35B |
| Average Diluted Shares Outstanding | 2.03B | 1.88B | 1.68B | 1.50B | 1.35B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | -- | -- | -- | -- |